Bullish Sentiment Across The Cannabis Space – Check Full Movers For March 22, 2022
GAINERS:
Item 9 Labs (OTC:INLB) shares closed up 12.61% at $1.25
The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings
Biotech stocks rebounded along with the broader market in the week ending March 18, as risk appetite returned. Multiple conference presentations, clinical readouts and earnings news dictated sentiment during the week.
Canaccord Genuity Maintains Buy on Cara Therapeutics, Lowers Price Target to $29
Canaccord Genuity analyst Sumant Kulkarni maintains Cara Therapeutics (NASDAQ:CARA) with a Buy and lowers the price target from $33 to $29.
HC Wainwright & Co. Maintains Buy on Cara Therapeutics, Lowers Price Target to $30
HC Wainwright & Co. analyst Oren Livnat maintains Cara Therapeutics (NASDAQ:CARA) with a Buy and lowers the price target from $35 to $30.
Marijuana Stock Movers For March 9, 2022
GAINERS:
MGC Pharmaceuticals (OTC:MGCLF) shares closed up 19.41% at $0.02
JP Morgan Upgrades Cara Therapeutics to Overweight, Raises Price Target to $20
JP Morgan analyst Jessica Fye upgrades Cara Therapeutics (NASDAQ:CARA) from Neutral to Overweight and raises the price target from $17 to $20.
Cara Therapeutics Reports Fourth Quarter And Full Year 2021 Financial Results
Cara Therapeutics, Inc. (NASDAQ: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the fourth quarter and full year ended December 31, 2021.
